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Stephen J. Pandol, MD,†† Aliye Uc, MD,‡‡ Zixi Zhu,§ and Dhiraj Yadav, MD, MPH§§Abstract: The lack of effective therapeutic agents specifically tailored for
chronic pancreatitis (CP) has hampered clinical care and negatively im-
pacted patients' lives. New mechanistic insights now point to novel thera-
pies, which involve both recently developed and/or repurposed agents.
This working group focused on 2 main outcomes for CP: pain and progres-
sion of disease. The goal is to frame the essential aspects of trial design in-
cluding patient-centered outcomes, proposed methods to measure the
outcomes of pain and progression, and study design considerations for fu-
ture trials to facilitate rapid drug development for patients with CP.
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sue their profession.5,6
There are limited effective therapeutic options for CP.
Therapy does exist for pancreatic exocrine insufficiency (ie,
pancreatic enzyme replacement therapy), although this therapy is
vastly underutilized, and complications of exocrine insufficiency
such as osteoporosis and fragility fractures are common in CP.
Similarly, therapy for pancreatic endocrine insufficiency is avail-
able, but type 3c diabetes may be quite brittle and difficult to man-
age. Unfortunately, abdominal pain, the most frequent and most
deleterious clinical consequence of CP, has no consistently effec-
tive therapy and greatly impairs patients' quality of life (QOL).
Similarly, no therapy has been demonstrated to consistently alter
the progression of CP.
The effectiveness of therapeutic agents has been difficult to
determine, as most previous studies utilized variable definitions,
metrics and instruments, duration of treatment, and end points
and lacked sham or placebo controls. In addition, very few studies
utilized patient-focused or patient-reported outcomes, and none
has reached the threshold of US Food and Drug Administration
(FDA) approval for CP pain. In addition to pain, therapies that
might impact progression, with perhaps the exception of alcohol
and smoking cessation, have rarely been studied. This working
group chose to focus on 4 main topics to help frame and harmo-
nize future studies, with a view to facilitating FDA consideration
and approval of these therapies These include (1) a review of the
need to incorporate patient experience and outcomes into future
trials and examples of how to achieve this; (2) a review of existing
research and knowledge on 2 main outcomes: abdominal pain
(and its impact) and progression of CP; (3) best practices for future
trials of pain associatedwithCP,with examples from other conditions
that would facilitate FDA approval; and (4) proposals for future trial
designs to test potential agents to prevent disease progression.
Further, we sought to identify major gaps in knowledge that pre-
vent progress in identifying and demonstrating the effectiveness
of therapies for both pain and progression of CP (Table 1).
PATIENT-FOCUSED DRUG DEVELOPMENT FOR
CP: INCORPORATING PATIENT INPUT IN
DEVELOPING TREATMENTS
The ultimate goal of drug development is to improve the way
that patients feel, function, and survive. The medical community
has recognized that patient perspectives might differ significantly
from what is anticipated by researchers, drug developers, and
providers, and what patients care most about may not always
be factored into clinical trials or approved labeling.7 This isPancreas • Volume 47, Number 10, November/December 2018
ealth, Inc. All rights reserved.
TABLE 1. Research Gaps and Opportunities
A. PFDD for CP: Incorporating Patient Input in Developing Treatments
• Comprehensively characterize the burden of disease, symptoms of most concern to patients, and patients' perspectives on
current treatment options.
• Identify subgroups that have different symptoms or different needs (including pediatric patients).
• Identify the clinical improvements that patients value most and the relative importance of different improvements.
• Determine how patients evaluate the trade-offs between potential benefits and risks of specific types of treatments.
• Determine the challenges of participating in clinical trials, especially reasons for dropout; gathering patient suggestions on how
clinical trials process and design can be improved.
B. Outcome Selection for CP-Related Pain
• Improve understanding of pain mechanisms and identify biomarkers (eg, in biological fluids, such as serum, pancreas fluid, urine) unique to
pain phenotype (eg, inflammatory or neuropathic) in individual patients, to allow appropriate patient selection for targeted intervention and
identification of novel therapies.
• Develop clinical algorithms for patient selection for clinical trials. For example, account for patient selection based on evidence of pancreatic
ductal anatomy, duration and character of pain, use of prior therapies, or presumed pain mechanism for selecting and stratifying patients for
future trials.
• Determine best instruments and end points for pain trials in CP. In particular, develop CP-specific QOL instruments, patient-focused end
points, and recommended core measures for consistency in future pain trials. Develop consensus primary and secondary outcomes and patient-
reported outcomes. Define appropriate duration of randomized pain therapy trials.
C. Outcome Selection for CP Progression–Related Outcomes
•Compare fibrosis in disease states to identify similarities and differences between fibrosis affecting different organs (eg, pancreas, liver, lungs).
• Develop new approaches to current imaging and novel imaging techniques to characterize different stages and progression of pancreatic
structure and function.
• Develop consensus clinical scoring systems, with patient input, as surrogate markers of disease progression.
• Define primary, secondary, and surrogate outcomes and end points for intervention trials.
D. Considerations for Pain-Centered Outcome Trials
• Facilitate incorporation of best practices of chronic pain trials into studies of CP pain.
• Develop consensus criteria on metrics and instruments for pain studies in CP.
• Inform regulatory agencies of best measures of pain outcome for CP.
E. Considerations for Natural History–Centered Outcome Trials
• Develop consensus criteria for inclusion and exclusion, patient-centered outcomes, disease-related manifestations, and disease progression
that can be used in randomized clinical trials for treatment of CP.
• Define accurate estimates of the frequency and determinants of progression in CP and of patient-centered and individual disease-related
events observed during the natural course of CP.
• Develop single or composite outcome measures for use in short-, intermediate-, and long-term studies focusing on progression of CP
(phases 2 and 3 studies).
• Develop surrogate panel consisting of biofluid markers to test biologic effect of an intervention for use in short-, intermediate-,
and long-term efficacy trials.
• Develop analytical methods for the joint analysis of multivariate survival and longitudinal data of mixed data types, for the exploration of
the disease progression heterogeneity, and for the validation of multivariate surrogate end points for CP progression.
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such as CP.
Patients with CP often suffer from debilitating pain, nausea,
and fatigue, which has a major impact on their ability to work,
attend school, tend to family responsibilities, and generally conduct
their activities of daily living.8 Yet, there is a paucity of research
about patient experiences and perspectives, in a way that might
guide researchers and drug developers. Patients' needs are largely
unmet, and patients and caregivers often feel misunderstood and
unsupported. For example, pain intensity has been a main target
of treatment trials. When it comes to evaluation of pain manage-
ment, however, a reduction in pain intensity is often less important
to patients than an improvement in overall function and daily activ-
ity.9 To adequately inform both drug development and evaluation, a
more comprehensive understanding of what patients truly seek
from treatment is necessary.
The pancreatic research community has recently begun to
bridge this knowledge gap. In a recent report, the Dutch Pancreatitis
Study Group surveyed 252 patients with acute pancreatitis (AP) or
CP regarding their symptoms, experience participating in clinical© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer research, and suggestions for future clinical research topics.10
The authors argue that the predominant patient-reported clinical
symptoms (eg, pain, fatigue) and future research topics suggested
by patients (eg, nutrition) contrast with those focused on by most
current studies, and therefore, a better understanding of patient
opinions and experiences should be a priority of future research.
Much more needs to be done to develop consistent measures
and instruments for clinical research in these patients.Patient-Focused Drug Development
In 2012, pursuant to a congressional mandate, the FDA estab-
lished the Patient-Focused Drug Development (PFDD) initiative,
with the goal of ensuring that “patients' experiences, perspectives,
needs, and priorities are captured and meaningfully incorporated
into drug development and evaluation.”11 This new focus on patients
in the drug development process was legally required under the Pre-
scription Drug User Fee Act V (2012), the 21st Century Cures Act
Section 3002 (2016), and Prescription Drug User Fee Act VI
(2017). The FDA has made significant progress in advancing PFDD,www.pancreasjournal.com 1201
Health, Inc. All rights reserved.
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gather patient perspectives about their conditions and available ther-
apies,12 and developing a series of 4 methodological guidance doc-
uments for collecting and submitting patient experience data.13
Armed with this new roadmap provided by the FDA, several
patient organizations have conducted pioneering work in collecting,
analyzing, and utilizing patient experience data to facilitate drug
development and regulatory decision making. The Duchenne
Muscular Dystrophy (DMD) community, for example, launched
a rigorous patient preference study to quantify patient benefit-
risk assessment, expanded the scope of acceptable end points
to include those that patients care most about, and submitted
a community-led draft industry guidance to the FDA. These ef-
forts have led to collaborations with the pharmaceutical industry
to develop drugs that directly address unmet needs for patients
with DMD (Fig. 1).14
Applying PFDD to CP
With congressional support for PFDD, FDA guidance,15 and
successful case examples from other patient groups, the CP com-
munity should apply the emerging paradigm of PFDD to its own
practice. The first step is to collect and analyze patient experience
data. With the newly published FDA guidance, “Patient-Focused
Drug Development: Collecting Comprehensive and Representa-
tive Input,”15 stakeholders should work collaboratively to collect
information on patient experiences and needs, about what improve-
ments patients and caregivers would most like to see, and about the
level of risk they are willing to tolerate. Patient-focused groups, in-
cluding Mission: Cure, a new nonprofit organization dedicated to
dramatically improving outcomes for CP patients, and the National
Pancreas Foundation, are able toworkwith thewider pancreas com-
munity and the FDA in this effort. The collected patient experi-
ence data will be a crucial step to guide drug discovery, inform
end point selection, and facilitate regulatory decision making.
OUTCOME SELECTION FOR CLINICAL TRIALS
CP and Pain
Previous cohort studies have documented that abdominal
pain is frequent (>75%) in patients with CP, that certain etiologiesFIGURE 1. Efforts made by the DMD community to bring patient input
1202 www.pancreasjournal.com
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pathic), that different pain patterns occur (eg, constant vs intermit-
tent), and that pain may evolve (or even burn out) over prolonged
follow-up.4,8,16–19 In patients with intermittent pain, which is
more common in the early stages of CP, there may be long periods
of freedom from pain. Pain is the most common reason for inter-
vention or hospitalization, and most detracts from QOL. Chronic
or continuous pain in particular has the most negative impact on
QOL in these patients.18 In the United States, approximately half
of all patients with CP are on opioid therapy,20 and this is far more
common than in many other countries. Many patients are on ad-
junctive agents (eg, tricyclic antidepressants, selective serotonin
reuptake inhibitors, and gabapentoids) as well. Although they
are recommended in guidelines,21,22 the impact and effectiveness
of these agents are not known. Endoscopic and surgical interven-
tion is possible in certain individuals with appropriate pancreatic
ductal anatomy, generally a dilated pancreatic duct, or an inflam-
matory mass in the head of the pancreas. The effectiveness of
these therapies on pain and the predictors of pain improvement
with these therapies are not clearly defined.21–24 Current therapies
are often ineffective, and chronic pain remains a dominant symp-
tom for many patients.
Approximately 80% of children with CP report abdominal
pain (approximately half have some form of constant pain), and
pain is the major driver of cost in the INSPPIRE population.25
Children with constant pain experience more emergency room visits,
miss more school, and require more hospitalizations compared with
thosewithout chronic pain.25,26 Forty-one percent of childrenwith
CP in INSPPIRE cohort use an opioid to control pain.27
Predicting patient response to a particular therapy for pain is
currently not possible. One confusing feature of this disease is that
the amount of damage to the pancreas (eg, that which is visible on
computed tomography [CT] scanning) does not correlate with the
severity or even presence of pain.28 Even therapies that appear to
work in a similar fashion (eg, endoscopic stenting or surgical de-
compression of a dilated pancreatic duct) may not have the same
effect in individual patients pointing out our lack of understanding
of the etiologies of symptoms in CP. The mechanisms of pain in CP
are complex, variable, and poorly understood. Some mechanisms of
pain include pancreatic inflammation and ischemia, intrapancreatic
nerve injury, altered nociception with sensitization, altered centralto facilitate drug development.
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
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effects of therapy (eg, narcotic bowel), and others.22,29 It is usually
difficult to identify the dominant pain mechanism in individual
patients, and thus, therapy becomes a matter of trial and error.
Underlying the problem in the study of pain in CP is the natural
variability of the symptoms and the diseases over time. Previous stud-
ies of pain therapies inCPhave used avariety ofmedical, endoscopic,
and surgical therapies, but few placebo-controlled trials exist.
Most trials are retrospective or prospective cohort studies, with a
small number of randomized (non–placebo controlled) trials.When
a placebo-treated group is used, a response of approximately 20%
is found in studies of CP pain.30 Most studies are cohort studies
without a control group. An additional source of variability can
be ascribed to the instrument utilized tomeasure pain and pain im-
provement. A few CP-specific pain assessment tools used in pre-
vious studies have utilized measures of pain severity and impact
on QOL (eg, Izbicki score).31 Others measure only the character
and temporal nature of the pain (such as the A-E, Ammann, or
Group 1–3 systems).31 In most randomized trials of therapy for
pain in CP, unidimensional studies of pain intensity, frequency,
or pattern have been used. In very limited studies, multidimen-
sional pain scores (eg, McGill Pain Questionnaire, Pain Detect
Questionnaire) and/or pain impact instruments (QOL scores,
Brief Pain Inventory, Pain Disability Index) have been utilized.31
Several expert consensus guidelines have recommended different
pain assessment tools for future studies.22,32–35 These recommen-
dations include visual analog scale pain tools, as well as some
measures of QOL using generic (Short Form 12, Patient-reported
Outcomes Measurement Information System, European Organiza-
tion for Research and Treatment Cancer Quality of Life Question-
naire C30) or CP-specific instruments (European Organization for
Research and Treatment Cancer Quality of Life Questionnaire
Pancreatic Modification). Three CP-specific QOL instruments
are available: European Organization for Research and Treatment
Cancer Quality of Life Questionnaire Pancreatic Modification,
Pancreatitis Quality of Life Instrument (now partially validated),36
and Comprehensive Pain Assessment Tool for Chronic Pancreatitis
(not yet validated).37 The recommendations from various guide-
lines do not specify the core measures recommended for chronic
pain trials.9CP and Progression
There is often a progression in patients, from AP to recurrent
AP to CP as a continuum over time. The pooled estimate of the
frequency of progression from AP to CP is 10% (95% confidence
interval, 6%–15%), with smoking and alcohol abuse in male sub-
jects being the strongest risk factors.38 Of note, many of these
studies did not analyze genetic predispositions, which are likely
to be additional predictors of progression to CP.
Imaging is a cornerstone of diagnosis and staging of CP, and
multiple imaging modalities have been assessed that focus on the
pancreatic ductal anatomy or pancreatic parenchyma.39 A well-
recognized challenge in diagnosis is that changes visible on these
imaging modalities develop over time and may be absent early in
the clinical course. A recent systematic review and meta-analysis40
noted similar diagnostic accuracy for endoscopic ultrasound (EUS),
magnetic resonance imaging (MRI), and CT in the initial diagnosis
of CP. However, none have been shown to have a strong relation-
ship with the symptoms patients report.
Endoscopic ultrasound-elastography and MRI-elastography
have the capability to qualitatively or quantitatively assess pancre-
atic stiffness as a marker of fibrosis.41–43 This method might en-
able staging and a platform to identify disease progression,
although no long-term follow-up of these techniques in individual© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer patients is available. Endoscopic ultrasound–elastography using
“mean of reflection” is able to grade pancreatic fibrosis through a
quantitative analysis into mild, marked or higher-grade fibrosis,
and severe fibrosis with areas under the receiver operating charac-
teristic curve of 0.90, 0.90, and 0.90, respectively.44 In a total of
115 patients, EUS-guided elastography allowed quantification of
the probability of exocrine insufficiency with an accuracy of
87.5%.45 Magnetic resonance imaging with secretin infusion, or
quantitative measures of MRI signal, may indicate the extent or
stage of CP,46,47 but MRI changes were only weakly correlated
with other staging criteria, such as the M-ANNHEIM classifica-
tion. Gland volume was negatively correlated to the duration of
CP (r = −0.39, P < 0.001) and baseline apparent diffusion coefficient
measured byMRI (r = −0.35, P = 0.027). When stratified by clinical
stage (M-ANNHEIM), the pancreatic gland volumewas significantly
decreased in the severe stages of CP (P = 0.001).48 Studies of EUS
and MRI suggest some potential for usefulness in clinical studies
but require more research to define the best techniques.
Parenchymal calcifications are considered a hallmark find-
ing of advanced CP, but these are not consistently linked to clinical
presentation and symptoms, and other morphological features
such as atrophy, fibrosis, and ductal changes. In a recent publica-
tion,49 number and size of parenchymal calcifications and any of
the other morphological CT and MRI parameters were not corre-
lated (all P > 0.05), with the exception of larger size of calcifica-
tions in thosewith higher number of calcifications. The number of
parenchymal calcifications was negatively correlated with body
mass index (r = −0.35, P = 0.0088) but not with any other clinical
parameter such as CP etiology or duration, M-ANNHEIM clinical
stage, tobacco or alcohol use, pain score, or QOL.49 This analysis
reinforces the concept that calcification alone is a poor metric for
measuring progression. Interestingly, parenchymal calcifications
are not a common feature of pediatric CP.26
The progression to exocrine and endocrine insufficiency ap-
pears to vary by etiology and particularly due to differences in the
natural history of alcoholic and idiopathic (nonalcoholic) CP.17
The development of exocrine or endocrine insufficiency usually
occurs after more than 5 years. The progression to exocrine insuf-
ficiency (86%–100%) and calcification (80%–91%) lasts 2- to
5-fold longer in idiopathic and some genetic types of CP if com-
pared with other forms of CP. The common early stage of CP,
characterized by recurrent pancreatitis, lasts up to 5-fold longer
in idiopathic CP if compared with CP due to alcohol.17,47,48,50 En-
docrine insufficiency is diagnosed in 8% of CP patients at the onset
of disease and in 78% at 10 years into the disease.17,51 As deterio-
ration of endocrine and exocrine function depends on the etiology
of the disease and occurs over many years, pancreatic function
alone may not be suitable as an end point for clinical trials.
Several scoring systems to evaluate the severity of CP exist.
The Cambridge classification for severity grading using endo-
scopic retrograde cholangiopancreatography,52 and its adaptation
for other types of imaging,21,53,54 is still used for diagnosing and
scoring of CP in adults. The ABC system uses a classification
consisting of 3 stages, which combine clinical criteria (pain, recur-
rent attacks of pancreatitis, local complications, steatorrhea, and
diabetes mellitus) with imaging (ductal or parenchymal changes).55
The Rosemont classification provides diagnosis and stages CP
using “major” and “minor” endoscopic ultrasonography criteria.56
The number of observed abnormalities correlates with the histo-
logic severity of the disease, but not with other clinical markers
of CP. The M-ANNHEIM classification is more comprehensive
and attempts to characterize patients according to etiology, clinical
stage, and severity.57 The severity of the inflammatory reaction is
evaluated using clinical symptoms and therapeutic interventions,
resulting in a rather complex classification criteria involving awww.pancreasjournal.com 1203
Health, Inc. All rights reserved.
Forsmark et al Pancreas • Volume 47, Number 10, November/December 2018point system describing severity of CP. The CP Prognostic Score
predicts individual short-term (12-month) prognosis using C-reactive
protein levels, thrombocyte count, glycosylated hemoglobin levels,
body mass index, and pain severity.58 This scoring system corre-
lated with the need for hospital admission and length of hospital
stay, but not with Cambridge grading. Similar to radiographic im-




Consistent with the findings in CP, our expanded knowledge
of pain in other chronic conditions has shown that the correlation
between objective findings and symptoms is not strong. In part
this is due to multiple etiologies and mechanisms for pain includ-
ing injury to nerve tissue, which can perpetuate pain even after the
original stimulus resolves. In treating many conditions, it is often
useful to use a disease-specific measure that combines the impor-
tant components of the disease into a single score. However, in
considering the treatment of persistent symptoms (ie, pain) that
continue despite improvement in the underlying disease, there is
evidence that combining symptoms may be inappropriate59 when
testing therapeutic interventions. When this is the case, as it is in
CP, different treatment approaches are needed to relieve symptoms,
and studies of pain-specific treatments for CP can be modeled after
other chronic pain conditions.
Over the past 20 years, there has been significant progress
made in understanding how to design, conduct, analyze, and inter-
pret pain studies. The 2 public-private partnerships of IMMPACT
and ACTTION have published more than 50 articles summarizing
thiswork (see IMMPACT.org and ACTTION.org). Studies of pain
therapeutics are required to have a measure of pain as the primary
outcome, and the 0- to 10-point numerical rating scale (NRS) of
average pain over the last 24-hour or 1-week period is the most
commonly used measure. Some studies use worst pain as a pri-
mary outcome, but recent work has demonstrated that both worst
and average pain measures perform similarly, leaving the choice to
be based on the likely effect of the treatment.60,61 Worst, least, and
average pain, as well as pain interference questions, are part of the
Brief Pain Inventory,62 which is one of the most widely used pain
outcome scales. Measurement frequency is widely discussed, but
many pain studies now collect the pain measure once daily (often
at bedtime to be consistent across time and easier to remember) and
average at least 4 to 5/7 days to achieve a stable weekly average.63,64
The growth in our understanding of the complexity of the
brain processes involved in the perception of pain has provided
important information relevant to the design of pain-focused clin-
ical trials. Nociceptive input is only 1 component leading to a
patient's report of pain. It is important to measure other aspects
of a patient's condition to understand the effect of the treatment being
studied. The primary categories of such characteristics have been
published from the consensus meetings of experts at IMMPACT.
These include (1) pain, (2) physical functioning, (3) emotional
functioning, (4) participant ratings of improvement and satisfaction
with treatment, (5) symptoms and adverse events, and (6) participant
disposition.65 An initial set of measures was defined in 2005,66 but
variations and updates3 have been explored for specific diseases.
A basis for all clinical trials is the assumption that subjects
will remain relatively stable in all other factors related to their
medical condition during the period of the study, such that we
may reasonably conclude that any changes observed during the
study period are attributable to the treatment being studied. This
is no less true for studies of pain and has important implications
for the design of such studies. First, many patients enrolled in pain1204 www.pancreasjournal.com
Copyright © 2018 Wolters Kluwer Hstudies are also on other treatments that may influence their
perception of pain, such as antidepressants, antianxiety, and
nonpharmacologic or local therapies. In general, as long as they
remain on stable doses over the period of the study, these should
not directly affect the outcome attributable to the study treatment.
Because it can be difficult to ask subjects to stop such medica-
tions, they often maintain their current levels rather than discon-
tinue. Second, although it is difficult to interpret whether a 0- to
10-point NRS pain score reported by 1 patient is better or worse
than a similar pain score reported by another patient, if both patients
report improved scores with treatment, we can conclude that their
pain improved. The 0- to 10-point NRS has significant benefits over
verbal descriptor or diagrammatic scales in its ease of use across
many different platforms (verbal, device, telephone, etc) and ease of
translation into almost any language. In addition to pain, it is impor-
tant to include measures of other outcomes that can reasonably be
assumed to be affected by the treatment as secondary outcomes,
which will support findings in the primary pain outcome.67
As with all symptomatic treatments, the brain-mediated
mind-body connection is an important consideration coupled
to patient expectation and the placebo response. This has in-
cluded methods to reduce the placebo group response on trial
outcome. However, it is important that a substantial amount
of the response noted in the placebo-treated group is due to
the natural history of disease and regression to the mean, which
applies to all subjects in the study. Some of the response is related
to the mind-body neurotransmitter-mediated process of the de-
scending inhibition of pain. Various run-in period processes have
been tried, but exclusion of “placebo responders” is generally dis-
couraged because a majority of these subjects are not true placebo
responders,68 and evidence from depression studies indicates it
can be counterproductive.69 Factors that may improve clinical trial
assay sensitivity have been suggested,70–72 but to date, only 1 fea-
ture has been demonstrated to help—excluding patients with ex-
tremely variable pain pattern during the baseline phase.73 Other
features that are thought to improve the conduct of clinical trials
include (1) careful phenotyping of patients enrolled74; (2) compre-
hensive assessment of patient characteristics to allow evaluation
of subgroups; (3) limited publication and communication of com-
plete study inclusion/exclusion criteria to avoid manipulation;
(4) standardization of the consent process and study personnel be-
havior to limit patient expectation; (5) central decision making
about inclusion of patients and randomization; (6) run-in periods
to test patient commitment to full participation; (7) measurement
strategies to minimize missing data by convenient collection
of daily pain data; and (8) training of patients in the use of
measurement scales.75
Finally, clinical trials need to be analyzed and presented in a
format that will be clinically relevant. The analysis must plan for
missing data including the use of mixed regression models and
sensitivity analyses with different assumptions about missing
data.76 Presentation of data can include means and standard devi-
ation but must also include responder analyses either using appro-
priate cutoff points within patients to identify responders60,77,78 or
by the presentation of data using cumulative distribution curves to
display data at all possible levels of response.79
CONSIDERATIONS FOR NATURAL
HISTORY–CENTERED OUTCOME TRIALS
The time to disease progression in CP is variable and depen-
dent on the age at presentation, presence of environmental risk
factors, genetic mutations, integrity of the main pancreatic duct,
and individual variability. While a large fraction of patients de-
velops 1 or more clinical symptoms (eg, AP attack(s), new-onset© 2018 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
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frame are infrequent andmay have competing influences on disease
course. Finally, as discussed previously, there are no well-accepted
criteria to evaluate disease progression based on either clinical
symptoms or imaging studies.
The goal of interventions to favorably alter the natural course
of CP is to reduce development of functional derangements and
morphologic destruction of the pancreas as well as the prevention
and treatment of clinical symptoms. To effectively test promising
treatments that may positively impact the course of CP, the dura-
tion of treatment and outcomes of interest need to be carefully
chosen. Trials that evaluate clinical symptoms of CP can be con-
ducted in a short (eg, pain, QOL) or intermediate (eg, frequency
and severity of AP, hospitalizations, QOL) time frame. The dura-
tion of observation could be a few weeks to 6 to 12 months for
short-term and 12 to 24 months for intermediate-term trials. Trials
that evaluate for objective end points of disease progression, such
as morphological disease progression, endocrine or exocrine
insufficiency, pancreatitis-related death, and the development
of pancreatic cancer, will need intermediate- to long-term obser-
vation period (3–5 or more years). As a result, these trials will
be lengthy and costly.
To accelerate translational research, there is an urgent need to
develop study designs or analytical methods that enable more
rapid conduct of these trials. One approach is to use alternative
end points that may change earlier than the recognizable progres-
sion events. End points consisting of longitudinal data of mor-
phology, biomarkers, AP/recurrent AP, new-onset diabetes, and
so on, can be used either individually or as a composite. However,
it is not easy to define an objective composite end point that can be
widely accepted. The CP Prognostic Score represents an attempt
for such an approach.58 Another approach is to validate short-
term change in longitudinal data as a “surrogate” end point for
long-term progression.80 There are specific criteria for validating
a surrogate end point: the surrogate end point and the long-term
end point must have strong association; that association must be
reproducible in the contexts of multiple studies, populations, and
interventions; the variation of the association in various popula-
tions should be well understood.80,81 In the case of translational
research of CP, there are additional analytical challenges.
It is necessary to obtain large-enough longitudinal cohort
data to study the validity of surrogate end points. The longitudinal
adult CP cohort study of the Consortium for the Study of Pancre-
atitis, Diabetes, and Pancreatic Cancer will be an important data
source, but other cohorts are also needed. Because CP is a multi-
faceted and heterogeneous disease, the short-term outcomes are
both multivariate and longitudinal, with mixed data types (ie, con-
tinuous, categorical, recurrent episodes). Validating the short-term
outcomes as surrogates for long-term outcomes requires joint
modeling of multivariate longitudinal data with mixed data types
and multivariate time-to-event data. Both statistical methods and
software for this kind of analysis are being developed in other dis-
ease areas but have not been applied to CP. The longitudinal tra-
jectory of these short-term outcomes may not be equal or
proportional as CP progresses. For example, as CP progresses to-
ward advanced stages, the inflammation in pancreatic tissue may
increase initially and then decrease as fibrosis increases. This phe-
nomenon causes difficulty in both composite end point definition
and statistical modeling of surrogate end points. Proper metrics
and methods are needed to evaluate the strength of association be-
tween short- and long-term outcomes, which constitutes part of
the evidence of surrogate end point validation. Because both the
short- and long-term outcomes are multivariate and longitudinal,
it is necessary to define clinically interpretable features from the
longitudinal data, with optimized prediction accuracy to the© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer long-term outcomes. Most surrogate end point methods were de-
veloped for evaluating a single end point, but multivariate surro-
gate end point should be considered for CP research due to the
heterogeneity of the disease.
Successful establishment of a short- to intermediate-term out-
come as a trial's end point, or validation of short- to intermediate-term
outcomes as surrogate end points for the long-term outcome, will
bring enormous benefits to the clinical research of CP: shorter-
duration trials, faster pace of translational research, increased statis-
tical power, reduced sample size and costs, and better understanding
of the association amongmultiple progression indicators andmul-
tiple types of clinical events.
In conclusion, current treatment options for CP are generally
limited to symptomatic management of disease manifestations,
which have not yet been carefully defined or measured. This doc-
ument frames the essential aspects of trial design, including the
importance of understanding and including patient-centered out-
comes, proposed methods to measure these outcomes, and study
design considerations to facilitate future studies for treatment of
pain and disease progression that produce drugs that most rapidly
reach patients.ACKNOWLEDGMENTS
The authors thank Annie Kennedy and Ryan Fischer from
Parent Project Muscular Dystrophy for sharing their experience
with PFDD. They also thank Wen-Hung Chen, PhD, from the
FDA for participating in the workshop. They thank Jason Tsai
from Abbvie Pharmaceuticals for his insights into the perspectives
of industry on new drug development and drug repurposing. The
authors especially thank patients and their families for participating
in our working group and presentations: Amy Jensen, Johnathan
Cole, Martin Cole, and Eric Golden.REFERENCES
1. Dufour MC, Adamson MD. The epidemiology of alcohol-induced
pancreatitis. Pancreas. 2003;27:286–290.
2. Spanier BW, Dijkgraaf MG, Bruno MJ. Trends and forecasts of hospital
admissions for acute and chronic pancreatitis in the Netherlands. Eur J
Gastroenterol Hepatol. 2008;20:653–658.
3. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic
cancer. Gastroenterology. 2013;144:1252–1261.
4. Ammann RW, Muellhaupt B. The natural history of pain in alcoholic
chronic pancreatitis. Gastroenterology. 1999;116:1132–1140.
5. Miyake H, Harada H, Kunichika K, et al. Clinical course and prognosis
of chronic pancreatitis. Pancreas. 1987;2:378–385.
6. Lankisch PG, Löhr-Happe A, Otto J, et al. Natural course in chronic
pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and
prognosis of the disease. Digestion. 1993;54:148–155.
7. US Food and Drug Administration (FDA). Plan for Issuance of
Patient-Focused Drug Development Guidance. 2017. Available at: https://
www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/
ucm563618.pdf. Accessed July 11, 2018.
8. Amann ST, Yadav D, Barmada MM, et al. Physical and mental quality of
life in chronic pancreatitis: a case-control study from the North American
Pancreatitis Study 2 cohort. Pancreas. 2013;42:293–300.
9. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design
considerations for confirmatory chronic pain clinical trials: IMMPACT
recommendations. Pain. 2010;149:177–193.
10. van Dijk SM, van Grinsven J, van Oostveen GJCB, et al. Patient input into
future clinical research in acute and chronic pancreatitis. Lancet
Gastroenterol Hepatol. 2018;3:452–453.www.pancreasjournal.com 1205
Health, Inc. All rights reserved.
Forsmark et al Pancreas • Volume 47, Number 10, November/December 201811. US Food and Drug Administration (FDA). CDER Patient-Focused Drug
Development. Available at: https://www.fda.gov/Drugs/
DevelopmentApprovalProcess/ucm579400.htm. Accessed June 2018.
12. US Food and Drug Administration (FDA). Patient-Focused Drug
Development: disease area meetings held in fiscal years 2013–2017.
Available at: https://www.fda.gov/ForIndustry/UserFees/
PrescriptionDrugUserFee/ucm347317.htm. Accessed June 2018.
13. US Food and Drug Administration (FDA). FDA Patient-Focused
Drug Development Guidance series for enhancing the incorporation
of the patient's voice in medical product development and
regulatory decision making. Available at: https://www.fda.gov/
Drugs/DevelopmentApprovalProcess/ucm610279.htm.
Accessed June 2018.
14. Biotechnology Innovation Organization & Parent Project Muscular
Dystrophy. Key considerations for developing & integrating patient
perspectives in drug development: examination of the Duchenne Case
Study. 2016. Available at: https://www.bio.org/sites/default/files/
BIO_PPMD_Paper_2016.pdf. Accessed July 11, 2018.
15. US Food and Drug Administration (FDA). Patient-Focused Drug
Development: collecting comprehensive and representative input.
Guidance for industry, Food and Drug Administration staff, and other
stakeholders draft guidance. 2018. Available at: https://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM610442.pdf. Accessed July 11, 2018.
16. Ammann RW, Akovbiantz A, Largiader F, et al. Course and outcome of
chronic pancreatitis. Longitudinal study of a mixed medical-surgical series
of 245 patients. Gastroenterology. 1984;86:820–828.
17. Layer P, Yamamoto H, Kalthoff L, et al. The different courses of early- and
late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology.
1994;107:1481–1487.
18. Mullady DK, Yadav D, Amann ST, et al. Type of pain, pain-associated
complications, quality of life, disability and resource utilisation in
chronic pancreatitis: a prospective cohort study. Gut. 2011;
60:77–84.
19. Machicado JD, Amann ST, Anderson MA, et al. Quality of life in chronic
pancreatitis is determined by constant pain, disability/unemployment,
current smoking, and associated co-morbidities. Am J Gastroenterol.
2017;112:633–642.
20. Nusrat S, YadavD, Bielefeldt K. Pain and opioid use in chronic pancreatitis.
Pancreas. 2012;41:264–270.
21. Löhr JM, Dominguez-Munoz E, Rosendahl J, et al. United European
Gastroenterology evidence-based guidelines for the diagnosis and therapy
of chronic pancreatitis (HaPanEU). United Eur Gastroenterol J. 2017;5:
153–199.
22. Drewes AM, Bouwense SAW, Campbell CM, et al. Working Group for the
International (IAP-APA-JPS-EPC) Consensus Guidelines for Chronic
Pancreatitis. Guidelines for the understanding and management of pain in
chronic pancreatitis. Pancreatology. 2017;17:720–731.
23. Rösch T, Daniel S, Scholz M, et al. Endoscopic treatment of chronic
pancreatitis: a multicenter study of 1000 patients with long-term follow-up.
Endoscopy. 2002;34:765–771.
24. Ahmed Ali U, Pahlplatz JM, Nealon WH, et al. Endoscopic or surgical
intervention for painful obstructive chronic pancreatitis. Cochrane
Database Syst Rev. 2015;CD007884.
25. Ting J, Wilson L, Schwarzenberg SJ, et al. Direct costs of acute recurrent
and chronic pancreatitis in children in the INSPPIRE registry. J Pediatr
Gastroenterol Nutr. 2016;62:443–449.
26. Schwarzenberg SJ, BellinM,Husain SZ, et al. Pediatric chronic pancreatitis
is associated with genetic risk factors and substantial disease burden.
J Pediatr. 2015;166:890–896.e1.
27. Morinville VD, Husain SZ, Bai H, et al. Definitions of pediatric pancreatitis
and survey of present clinical practices. J Pediatr Gastroenterol Nutr. 2012;
55:261–265.1206 www.pancreasjournal.com
Copyright © 2018 Wolters Kluwer H28. Wilcox CM, Yadav D, Ye T, et al. Chronic pancreatitis pain pattern and
severity are independent of abdominal imaging findings. Clin
Gastroenterol Hepatol. 2015;13:552–560; quiz e28-e29.
29. Olesen SS, Krauss T, Demir IE, et al. Towards a neurobiological
understanding of pain in chronic pancreatitis: mechanisms and implications
for treatment. Pain Rep. 2017;2:e625.
30. Capurso G, Cocomello L, Benedetto U, et al. Meta-analysis: the placebo
rate of abdominal pain remission in clinical trials of chronic pancreatitis.
Pancreas. 2012;41:1125–1131.
31. TeoK, JohnsonMH, Truter S, et al. Pain assessment in chronic pancreatitis:
a comparative review of methods. Pancreatology. 2016;16:931–939.
32. Delhaye M, Van Steenbergen W, Cesmeli E, et al. Belgian consensus on
chronic pancreatitis in adults and children: statements on diagnosis and
nutritional, medical, and surgical treatment. Acta Gastroenterol Belg. 2014;
77:47–65.
33. Frulloni L, Falconi M, Gabbrielli A, et al. Italian consensus guidelines for
chronic pancreatitis. Dig Liver Dis. 2010;42(suppl 6):S381–S406.
34. Anderson MA, Akshintala V, Albers KM, et al. Mechanism, assessment
and management of pain in chronic pancreatitis: recommendations of a
multidisciplinary study group. Pancreatology. 2016;16:83–94.
35. Mayerle J, Hoffmeister A,Werner J, et al. Chronic pancreatitis—definition,
etiology, investigation and treatment.Dtsch Arztebl Int. 2013;110:387–393.
36. Wassef W, DeWitt J, McGreevy K, et al. Pancreatitis quality of life
instrument: a psychometric evaluation. Am J Gastroenterol. 2016;111:
1177–1186.
37. Teo K, Johnson MH, Drewes AM, et al. A Comprehensive Pain
Assessment Tool (COMPAT) for chronic pancreatitis: development,
face validation, and pilot evaluation. Pancreatology. 2017;17:706–719.
38. Sankaran SJ, Xiao AY, Wu LM, et al. Frequency of progression from acute
to chronic pancreatitis and risk factors: a meta-analysis. Gastroenterology.
2015;149:1490–1500.e1.
39. Anaizi A, Hart PA, Conwell DL. Diagnosing chronic pancreatitis. Dig Dis
Sci. 2017;62:1713–1720.
40. Issa Y, Kempeneers MA, van Santvoort HC, et al. Diagnostic performance
of imaging modalities in chronic pancreatitis: a systematic review and
meta-analysis. Eur Radiol. 2017;27:3820–3844.
41. Kawada N, Tanaka S. Elastography for the pancreas: current status and
future perspective.World J Gastroenterol. 2016;22:3712–3724.
42. Iglesias-Garcia J, Domínguez-Muñoz JE, Castiñeira-Alvariño M, et al.
Quantitative elastography associated with endoscopic ultrasound for the
diagnosis of chronic pancreatitis. Endoscopy. 2013;45:781–788.
43. Wang M, Gao F, Wang X, et al. Magnetic resonance elastography and T1
mapping for early diagnosis and classification of chronic pancreatitis.
J Magn Reson Imaging. 2018 Mar 14. [Epub ahead of print].
44. Itoh Y, Itoh A, Kawashima H, et al. Quantitative analysis of diagnosing
pancreatic fibrosis using EUS-elastography (comparison with surgical
specimens). J Gastroenterol. 2014;49:1183–1192.
45. Dominguez-Muñoz JE, Iglesias-Garcia J, Castiñeira Alvariño M, et al.
EUS elastography to predict pancreatic exocrine insufficiency in
patients with chronic pancreatitis. Gastrointest Endosc. 2015;81:
136–142.
46. Tirkes T, Lin C, Cui E, et al. Quantitative MR evaluation of chronic
pancreatitis: extracellular volume fraction and MR relaxometry. AJR Am
J Roentgenol. 2018;210:533–542.
47. Chamokova B, Bastati N, Poetter-Lang S, et al. The clinical value of
secretin-enhanced MRCP in the functional and morphological assessment
of pancreatic disease. Br J Radiol. 2018;91:20170677.
48. Madzak A, Olesen SS, Haldorsen IS, et al. Secretin-stimulated MRI
characterization of pancreatic morphology and function in patients with
chronic pancreatitis. Pancreatology. 2017;17:228–236.© 2018 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
Pancreas • Volume 47, Number 10, November/December 2018 CP Drug Development: NIDDK Working Group Summary49. Andersen PL, Madzak A, Olesen SS, et al. Quantification of parenchymal
calcifications in chronic pancreatitis: relation to atrophy, ductal changes,
fibrosis and clinical parameters. Scand J Gastroenterol. 2018;53:218–224.
50. Müllhaupt B, Truninger K, Ammann R. Impact of etiology on the painful
early stage of chronic pancreatitis: a long-term prospective study.
Z Gastroenterol. 2005;43:1293–1301.
51. Lankisch PG. Natural course of chronic pancreatitis. Pancreatology.
2001;1:3–14.
52. SarnerM, Cotton PB. Classification of pancreatitis.Gut. 1984;25:756–759.
53. Hoffmeister A, Mayerle J, Beglinger C, et al. English language version of
the S3-consensus guidelines on chronic pancreatitis: definition, aetiology,
diagnostic examinations, medical, endoscopic and surgical management
of chronic pancreatitis. Z Gastroenterol. 2015;53:1447–1495.
54. Conwell DL, Lee LS, Yadav D, et al. American Pancreatic Association
Practice Guidelines in Chronic Pancreatitis: evidence-based report on
diagnostic guidelines. Pancreas. 2014;43:1143–1162.
55. Büchler MW, Martignoni ME, Friess H, et al. A proposal for a new clinical
classification of chronic pancreatitis. BMC Gastroenterol. 2009;9:93.
56. Catalano MF, Sahai A, Levy M, et al. EUS-based criteria for the diagnosis
of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc.
2009;69:1251–1261.
57. Schneider A, Löhr JM, Singer MV. The M-ANNHEIM classification of
chronic pancreatitis: introduction of a unifying classification system based
on a review of previous classifications of the disease. J Gastroenterol.
2007;42:101–119.
58. Beyer G, Mahajan UM, Budde C, et al. Development and validation of a
chronic pancreatitis prognosis score in 2 independent cohorts.
Gastroenterology. 2017;153:1544–1554.e2.
59. Griffith JW, Stephens-Shields AJ, Hou X, et al. Pain and urinary symptoms
should not be combined into a single score: psychometric findings from the
MAPP research network. J Urol. 2016;195:949–954.
60. Farrar JT, Pritchett YL, Robinson M, et al. The clinical importance of
changes in the 0 to 10 numeric rating scale for worst, least, and average pain
intensity: analyses of data from clinical trials of duloxetine in pain
disorders. J Pain. 2010;11:109–118.
61. Smith SM, JensenMP, He H, et al. A comparison of the assay sensitivity of
average and worst pain intensity in pharmacologic trials: an ACTTION
systematic review and meta-analysis. J Pain. 2018;19:953–960.
62. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain
Inventory. Ann Acad Med Singapore. 1994;23:129–138.
63. Jensen MP, McFarland CA. Increasing the reliability and validity of pain
intensity measurement in chronic pain patients. Pain. 1993;55:195–203.
64. Younger J, McCue R, Mackey S. Pain outcomes: a brief review of
instruments and techniques. Curr Pain Headache Rep. 2009;13:39–43.
65. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic
pain clinical trials: IMMPACT recommendations. Pain. 2003;106:
337–345.© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer 66. Dworkin RH, Turk DC, Farrar JT, et al. Core outcomemeasures for chronic
pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9–19.
67. Taylor AM, Phillips K, Patel KV, et al. Assessment of physical function and
participation in chronic pain clinical trials: IMMPACT/OMERACT
recommendations. Pain. 2016;157:1836–1850.
68. Dworkin RH,McDermott MP, Farrar JT, et al. Interpreting patient treatment
response in analgesic clinical trials: implications for genotyping,
phenotyping, and personalized pain treatment. Pain. 2014;155:457–460.
69. Dworkin RH, Katz J, Gitlin MJ. Placebo response in clinical trials of
depression and its implications for research on chronic neuropathic pain.
Neurology. 2005;65(12 suppl 4):S7–S19.
70. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for
improving assay sensitivity in chronic pain clinical trials: IMMPACT
recommendations. Pain. 2012;153:1148–1158.
71. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Assay sensitivity and study
features in neuropathic pain trials: an ACTTIONmeta-analysis. Neurology.
2013;81:67–75.
72. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Meta-analysis of assay
sensitivity and study features in clinical trials of pharmacologic treatments
for osteoarthritis pain. Arthritis Rheumatol. 2014;66:3327–3336.
73. Farrar JT, Troxel AB, Haynes K, et al. Effect of variability in the 7-day
baseline pain diary on the assay sensitivity of neuropathic pain randomized
clinical trials: an ACTTION study. Pain. 2014;155:1622–1631.
74. Edwards RR, Dworkin RH, Turk DC, et al. Patient phenotyping in clinical
trials of chronic pain treatments: IMMPACTrecommendations.Pain. 2016;
157:1851–1871.
75. Smith SM, Amtmann D, Askew RL, et al. Pain intensity rating training:
results from an exploratory study of the ACTTION PROTECCT system.
Pain. 2016;157:1056–1064.
76. National Research Council (US) Panel on Handling Missing Data in
Clinical Trials. The Prevention and Treatment of Missing Data in Clinical
Trials. Washington, DC: The National Academies Press; 2010.
77. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes
in chronic pain intensity measured on an 11-point numerical pain rating
scale. Pain. 2001;94:149–158.
78. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical
importance of treatment outcomes in chronic pain clinical trials:
IMMPACT recommendations. J Pain. 2008;9:105–121.
79. Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of
responders analysis graph to present pain data over a range of cut-off points:
making clinical trial data more understandable. J Pain Symptom Manage.
2006;31:369–377.
80. Burzkowski T, Molenberghs G, BuyseM, eds. The Evaluation of Surrogate
Endpoints. New York, NY: Springer; 2005.
81. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical
trials. Stat Med. 2012;31:2973–2984.www.pancreasjournal.com 1207
Health, Inc. All rights reserved.
